Clinical Trials Logo
  1. Home
  2. Advanced Malignancy
  3. NCT02978482

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy Clinical Trial

Official title:
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in Combination With Tremelimumab in Chinese Patients With Advanced Malignancies

Clinical Trial Summary

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in combination with tremelimumab in Chinese Patients with Advanced Malignancies

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02978482
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date December 1, 2016
Completion date November 26, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00978926 - A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies N/A
Completed NCT01444404 - A Study of AMG 820 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT00428545 - Bevacizumab and Bortezomib in Patients With Advanced Malignancy Phase 1
Completed NCT02743637 - A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors Phase 1
Completed NCT01558817 - Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation With Informed Assent N/A
Completed NCT01253707 - A Study of AMG 337 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01723020 - A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma Phase 1
Completed NCT00813384 - A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT00974896 - QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors Phase 1
Completed NCT02110355 - A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma Phase 1
Completed NCT00858377 - A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors Phase 1
Completed NCT04216082 - A Study of Anlotinib in Subjects With Advanced Malignancy Phase 2
Terminated NCT02437916 - Safety Study of AMG 228 to Treat Solid Tumors Phase 1
Terminated NCT01231347 - QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Phase 3
No longer available NCT01945164 - XL999 Administered Intravenously to a Subject With Advanced Malignancies N/A
Completed NCT03875157 - Study of IBI318 in Participants With Advanced Malignancies Phase 1
Completed NCT02016729 - A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia Phase 1